From Stalled to Accelerated
Sapian compresses the lead identification phase from years of unsuccessful high throughput screening to a few weeks of discovery.
PATIENTS ARE WAITING...
LET'S ACCELERATE
The missing engine in modern discovery pipeline
You have the biological expertise and the testing infrastructure — but your target remains “undruggable.” Many of our partners reach a standstill when traditional screening or docking fails to produce viable chemical starting points. You possess the sophisticated assays and the validation models, yet the right candidate molecules remain elusive.
Sapian fills that gap. Sapian is a high-velocity in silico engine to identify the precise molecules your infrastructure was built to test, moving our partners from a “stalled target” to a “validated lead” in record time.
THE SAPIAN EDGE
THE NEXT ERA OF PRECISION
Traditional High-Throughput Screening (HTS) is a multi-year gamble. We replace physical trial-and-error with high-precision digital prediction, feeding your wet lab with high-probability candidates.
Unmatched Scale
Sapian scans 10 billion molecules per day. We perform the digital equivalent of 200 years of lab work in a single day to find the “needle in the haystack.”
100% In Silico
Sapian doesn’t require physical libraries until very late. Only the highly promising candidates get to be experimentally tested, a lean and efficient approach.
Superior Hit Rates
Our partners see validation rates of 10%–90% (vs the industry average of <0.1%). We de-risk your research by ensuring your lab only tests the most promising molecules.
HOW THE PARTNERSHIP SYNCHRONIZES
1 / Project Start
You provide a target where candidate molecules are currently lacking. No further data is needed.
2 / Hit Prediction
Sapian™ conducts a massive-scale virtual search and optimization. No physical materials are needed from your side during this phase.
3 / Lab Validation
You utilize your existing testing infrastructure to validate a hyper-targeted shortlist of AI-predicted molecules and possibly key endpoints.
4 / Hit to Lead
Sapian™ uses data from the initial hits to optimize further around the new chemotypes. It predicts critical properties such as whole-proteome selectivity, hERG, and filters out IP-protected chemical families.
5 / Lab Validation
You apply the same testing infrastructure validation while validating any critical endpoint.
6 / Result
We arrive at a validated lead series ready for final optimization, cutting R&D cycle by up to 75%, and having mitigated some off-target effects with years of advance.
Our partners include top-10 global biopharma companies, leading academic and hospital research labs, and patient organizations, including Johns Hopkins University School of Medicine, French Centre for Stem Cell Research, Institut Bergonié, INSERM, Nanyang University of Technology, Nantes University, Necker Hospital, Institute for Plant Molecular Biology, CNRS, University of Antwerpen.
